[OR17-1] Long-Term Follow-Up of Patients with Type 1 Diabetes on Liraglutide and the Effect of Liraglutide as Additional Treatment in Obese Patients with Type 1 Diabetes

Nitesh D Kuhadiya, Ritu Malik, Natalie Bellini, Jane Lyons Patterson, Andrea Traina, Antoine Makdissi, Paresh Dandona. State University of New York (SUNY), Buffalo, NY; Rochester General Hospital, Rochester, NY; St John Fisher College, Rochester, NY.

We have recently shown that the addition of Liraglutide to insulin in the treatment of well controlled, non-obese patients with type 1 diabetes leads to a significant further rapid reduction in glycemia, glycemic excursions, HbA1c, insulin requirements and body weight within days. We now present data of 8 patients with type 1 diabetes (mean age: 43±8 yrs; mean duration of diabetes: 29±11 yrs) on Liraglutide treatment (mean dose: 1.72±0.67mg) for 1.24± 0.21 yrs. Percent time spent in hyperglycemia calculated by using 3 glycemic thresholds (>150,200 and 250 mg/dl) fell by 45.35%(p = 0.01), 45.19%(p = 0.03) & 61.92%(p =0.001) respectively. There was a reduction in the bolus, basal and total daily doses of insulin by 26%(p = 0.009), 19%(p = 0.01) and 20%(p = 0.008) respectively. The body weight fell from 85.3± 12.6 to 78.7±15.9 Kg (p = 0.01) and the BMI from 30.3 ± 3.9 to 27.8 ±4.9Kg/m2 (p = 0.01). Fasting C-peptide concentrations were non-detectable at the outset and at the end of the study. We have now also investigated the effect of the addition of 1.8 mg of Liraglutide in 15 obese patients with type 1 diabetes (10 females, 5 males, 14 Caucasian, 1 African American; mean age: 47 ±13.81 yrs; mean duration of diabetes: 20.06 ± 10.18 yrs) who were not well controlled (mean HbA1c: 7.8±0.82). Over a period of 6 months, HbA1c fell to 7.39± 0.77%(p = 0.05); the bolus dose of insulin decreased significantly from 35.92 ± 19.69 to 29.52 ± 17.10 units (p = 0.03) while the basal dose did not change; the body weight fell from 100.63 ± 18.31 Kg to 95.96±19.22 kg (p = 0.008) and the BMI from 34.06±7.36 to 32.33±6.85 Kg/m2 (p = 0.01). The systolic BP decreased from 137.53± 18.86 to 121.86±13.53(p = 0.003). We conclude that Liraglutide treatment in patients with type 1 diabetes has a rapid, sustained and durable effect on glycemia, body weight, insulin dose and systolic blood pressure. In addition, poorly controlled, obese patients with type 1 diabetes also benefit from this treatment. Large, prospectively randomized studies are required to establish the use of Liraglutide in type 1 diabetes. Mechanistic studies to elucidate the mode of action of Liraglutide in these patients are also required since they do not have any beta-cell reserve.

Sources of Research Support: This research was not funded.

Disclosures: PD: Speaker, Novo Nordisk; Principal Investigator, Novo Nordisk; Advisory Group Member, Novo Nordisk. Nothing to Disclose: NDK, RM, NB, JLP, AT, AM

Date: Sunday, June 24, 2012
Session Info: ORAL SESSION: Emerging Strategies in Diabetes (11:15 AM-12:45 PM)
Presentation Time: 11:15 am
Room: Theater C

Embargo Policy
Unless otherwise noted, all abstracts presented at ENDO are embargoed until the date and time of presentation. Abstracts presented at a news conference are embargoed until the date and time of the news conference. The Endocrine Society reserves the right to lift the embargo on specific abstracts that are selected for promotion prior to or during ENDO.

Disclaimer Statement
The information presented at ENDO news conferences and within the Research Summaries Book represents the opinion of the presenters and authors and is not necessarily the view of The Endocrine Society. The Endocrine Society makes no representation as to the truth or warranty, accuracy, or originality of the information presented.

For additional information, please contact The Endocrine Society’s Public Affairs Department at 240-482-1380 or alohr@endo-society.org.


Close Window